UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2026

Commission File Number: 001-40753

ICECURE MEDICAL LTD.
(Translation of registrant's name into English)

7 Ha'Eshel St., PO Box 3163
Caesarea, 3079504 Israel
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On November 2, 2026, IceCure Medical Ltd. (the "Company") convened its Annual and Special General Meeting of Shareholders (the "Meeting").

The Meeting was initially adjourned due to there not being a required quorum present to open and conduct it at the initial time of 5:00 p.m. (Israel time). However, the adjourned Meeting was held at 6:30 p.m. (Israel time). At the adjourned Meeting, a quorum was present, and the shareholders of the Company voted upon and approved the agenda items that were described in the Company's proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission ("SEC") on October 5, 2026 (the "Proxy Statement").

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (File Nos.333-297030, 333-290046 and 333-258660) and Form S-8 (File Nos. 333-298361, 333-270982, 333-264578, 333-262620 and 333-281587), filed with the SEC, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IceCure Medical Ltd.

Date: November 2, 2026

By: /s/ Eyal Shamir
Name: Eyal Shamir
Title: Chief Executive Officer